AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3.8 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

DNA methylation heterogeneity in complex tumor microenvironment: Quantitative methods, influencing factors, and clinical implications

Yongle Xua,c, Shuangyue Maa,b,c, Manyi Xua,c, Hongbo Zhua, Yuncong Wanga, Wenbo Donga, Jing Gana, Yusen Zhaoa, Xinrong Lia, Shuangshuang Wanga, Haoyu Hua, Jiaheng Hea, Shangwei Ninga( ), Hui Zhia( )
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China
Liangzhu Laboratory, Zhejiang University, Hangzhou, Zhejiang 311121, China

c These authors contributed equally to this work.

Peer review under the responsibility of Chongqing Medical University.

Show Author Information

Abstract

5-Methylcytosine (5-mC) is the most prevalent DNA methylation modification in the human genome, and its abnormal patterns are strongly associated with tumor progression. Intratumoral and intertumoral DNA methylation heterogeneity (DNAmeH) primarily arises from cancer epigenome heterogeneity and the diverse cell compositions within the tumor microenvironment (TME). Furthermore, recent advancements in high-throughput sequencing and microarray technologies have facilitated the development of quantitative methods for measuring DNAmeH, enabling a more thorough exploration of the factors influencing it. Moreover, investigating various DNA methylation patterns at the single-cell level within the intricate TME sheds light on DNAmeH being driven by cellular heterogeneity. In addition, accumulating studies on the selection of methylation biomarkers in tissue or circulating DNA elucidate the cell specificity of DNA methylation, which is valuable for early cancer detection and personalized therapy. In this review, we elucidate the characteristics of intratumoral and intertumoral DNAmeH, considering DNAmeH differences across cancer types, among individual cells, and at allele-specific hemimethylation sites. Several metrics are summarized to quantitatively assess DNAmeH. We evaluate the factors that influence DNAmeH via these metrics, including the cell cycle phase, tumor mutational burden (TMB), cellular stemness, copy number variation (CNV), tumor subtype, tumor characteristics, tumor stage, state of tumor cells, hypoxia, and tumor purity. Finally, we highlight the deconvolution of TME cellular components and the application of predictive methylation biomarkers in cancer clinical research.

References

【1】
【1】
 
 
Genes & Diseases

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Xu Y, Ma S, Xu M, et al. DNA methylation heterogeneity in complex tumor microenvironment: Quantitative methods, influencing factors, and clinical implications. Genes & Diseases, 2026, 13(3). https://doi.org/10.1016/j.gendis.2025.101832

848

Views

3

Downloads

2

Crossref

1

Web of Science

1

Scopus

0

CSCD

Received: 20 November 2024
Revised: 09 May 2025
Accepted: 20 July 2025
Published: 25 August 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).